Insulin resistance parameters in users of the injectable contraceptive depot medroxyprogesterone acetate during one year of use

European Journal of Contraception and Reproductive Health Care

Volumn 21, Issue 1, 2016, Pages 22-29

  Cursino, Kleber ^a   Sider, Marina ^a   Pavin, Elizabeth João ^b   De Nazaré Silva Dos Santos, Priscilla ^a   Bahamondes, Luis ^a   Zantut Wittmann, Denise Engelbrecht ^b   Fernandes, Arlete ^a  

^a Department of Obstetrics and Gynaecology ^*  (Brazil)

^b UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

Contraception; Depot medroxyprogesterone acetate; HOMA index; Insulin resistance

Indexed keywords

GLUCOSE; INSULIN; MEDROXYPROGESTERONE ACETATE; NORETHISTERONE ENANTATE; CONTRACEPTIVE AGENT;

ADULT; ANTHROPOMETRIC PARAMETERS; ARTICLE; ASSESSMENT OF HUMANS; BODY MASS; CARBOHYDRATE METABOLISM; CLINICAL ASSESSMENT; CLINICAL EVALUATION; COMPARATIVE STUDY; CONTRACEPTIVE BEHAVIOR; CONTROLLED STUDY; DIET RESTRICTION; FEMALE; HOMEOSTASIS MODEL ASSESSMENT; HUMAN; INSULIN RESISTANCE; INTRAUTERINE CONTRACEPTIVE DEVICE; MAJOR CLINICAL STUDY; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; WAIST CIRCUMFERENCE; ADVERSE EFFECTS; BODY COMPOSITION; DRUG EFFECTS; FOLLOW UP; OBESITY; RISK FACTOR; WEIGHT GAIN; YOUNG ADULT;

ADIPOSITY; ADULT; BODY COMPOSITION; BODY MASS INDEX; CONTRACEPTIVE AGENTS, FEMALE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INSULIN RESISTANCE; INTRAUTERINE DEVICES, MEDICATED; MEDROXYPROGESTERONE ACETATE; PROSPECTIVE STUDIES; RISK FACTORS; WEIGHT GAIN; YOUNG ADULT;

EID: 84953775955     PISSN: 13625187     EISSN: 14730782     Source Type: Journal    
DOI: 10.3109/13625187.2015.1059415     Document Type: Article

References (22)

1. Fraser IS, Weisberg E A comprehensive review of injectable contraception with special emphasis on depot medroxyprogesterone acetate. Med J Aust 1981; 1 (1 Suppl): 3-19.
2. Gershberg H, Zorrilla E, Hernandez A, Hulse M. Effects of medroxyprogesterone acetate on serum insulin and growth hormone levels in diabetics and potential diabetics. Obstet Gynecol 1969; 33: 383-9.
3. Nash HA. Depo Provera: A review. Contraception 1975; 12: 377-93.
4. Lopez LM, Grimes DA, Schulz KF. Steroidal contraceptives: Effect on carbohydrate metabolism in women without diabetes mellitus. Cochrane Database Syst Rev 2014; 4:C D006133.
5. Amatayakul K, Svassomboon B, Singkamani R. Effects of medroxyprogesterone acetate on serum lipids, protein, glucose tolerance, and liver function in Thai women. Contraception 1980; 21: 283-97.
6. Fahmy K, Abdel-Razik M, Shaaraway M, et al. Effect of long-Acting progestagen-only injectable contraceptives on carbohydrate metabolism and its hormonal profile. Contraception 1991; 44: 419-30.
7. Liew DF, Ng CS, Yong YM, Ratnam SS. Long-Term effects of Depo-Provera on carbohydrate and lipid metabolism. Contraception 1985; 31: 51-64.
8. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: A method for quantifying insulin secretion and resistance. Am J Physiol 1979; 237: E214-23.
9. Bonora E, Targher G, Alberiche M, et al. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: Studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care 2000; 23: 57-63.
10. Chang AM, Smith MJ, Bloem CJ, et al. Limitation of the homeostasis model assessment to predict insulin resistance and beta-cell dysfunction in older people. J Clin Endocrinol Metab 2006; 91: 629-34.
11. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-19.
12. Katsuki A, Sumida Y, Gabazza EC, et al. Homeostasis model assessment is a reliable indicator of insulin resistance during follow-up of patients with type 2 diabetes. Diabetes Care 2001; 24: 362-5.
13. Hanley AJ, Williams K, Stern MP, Haffner SM. Homeostasis model assessment of insulin resistance in relation to the incidence of cardiovascular disease: The San Antonio Heart Study. Diabetes Care 2002; 25: 1177-84.
14. Clark MK, Dillon JS, Sowers M, Nichols S. Weight, fat mass, and central distribution of fat increase when women use depot-medroxyprogesterone acetate for contraception. Int J Obes (Lond) 2005; 29: 1252-8.
15. Berenson AB, Rahman M. Changes in weight, total fat, percent body fat, and central-To-peripheral fat ratio associated with injectable and oral contraceptive use. Am J Obstet Gynecol 2009; 200:329. e1-8.
16. ABEP. [Brazilian Association of Research Companies.] [ The Brazilian Economic Classification Criteria, 2009.] Accessed 27 May 2015 from: http://www.abep.org/criterioBrasil.aspx
17. World Health Organization. Global recommendations on physical activity for health. Geneva: WHO 2011.
18. World Health Organization. Physical status: The use and interpretation of anthropometry. World Health Organ Tech Rep Ser 1995; 854: 1-452.
19. Geloneze B, Vasques AC, Stabe CF, et al.; BRAMS Investigators. HOMA1-IR and HOMA2-IR indexes in identifying insulin resistance and metabolic syndrome: Brazilian Metabolic Syndrome Study (BRAMS). Arq Bras Endocrinol Metabol 2009; 53: 281-7.
20. Tam CS, Xie W, Johnson WD, et al. Defining insulin resistance from hyperinsulinemic-euglycemic clamps. Diabetes Care 2012; 35: 1605-10.
21. Winner B, Peipert JF, Zhao Q, et al. Effectiveness of long-Acting reversible contraception. N Engl J Med 2012; 366:1998v2007.
22. Vickery Z, Madden T, Zhao Q, et al. Weight change at 12 months in users of three progestin-only contraceptive methods. Contraception 2013; 88: 503-8.